Lantheus Holdings (LNTH)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$100.97-0.01%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
QuarterlyIQ Insights · LNTH
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -30.8% |
| Our one-year growth estimate | diamond | 4.6% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 35.4 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 23 industry peers · Company calendar date is not available
LNTH — officer change
Dated 2026-08-03
The filing details transaction bonuses and amended severance agreements for certain executive officers in connection with a proposed merger.
Why it matters: Cash flow is vital for funding operations and growth. A decline could indicate financial stress.
Worry ifCash flow from operations drops below $100 million in Q2 2026.
Less concerning ifCash flow from operations remains above $100 million in Q2 2026.
Why it matters: FDA approval will impact Lantheus's ability to launch new products and drive revenue growth.
Supportive ifLNTH-2501 receives FDA approval by the extended PDUFA date of June 29, 2026.
Worry ifFDA does not approve or delays the decision past the new PDUFA date.
Why it matters: A drop in sector growth could impact Lantheus's performance and outlook.
Worry ifSector revenue growth reported below 8% year over year.
Less concerning ifSector revenue growth remains above 8% year over year.
Why it matters: A change in adjusted EPS guidance can show how much management believes in future earnings.
Watch forManagement raises adjusted EPS guidance to above $5.25 for 2026. This shows strong performance.
Also watch forManagement cuts adjusted EPS guidance to below $5.00. This shows there are operational issues.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$83 on $10,000 · ±0.8% | How much price usually moves either way. |
| Bad day | $290 loss on $10,000 · 2.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $1,280 loss on $10,000 · 12.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Sustained revenue growth is crucial for Lantheus's long-term strategy. It shows the effectiveness of their product portfolio.
Supportive ifQ2 2026 revenue growth exceeds 1.5% compared to Q2 2025.
Worry ifQ2 2026 revenue growth is below 1.5% compared to Q2 2025.
Why it matters: Higher operating income means better cost control and efficiency. This helps profits.
Supportive ifOperating income increases from Q1 2026 to Q2 2026.
Worry ifOperating income declines or remains flat from Q1 2026 to Q2 2026.
Why it matters: Hitting revenue goals is important for investor trust and stock performance.
Supportive ifQ2 revenue meets or exceeds the guidance range of $1.4 billion to $1.45 billion.
Worry ifQ2 revenue falls below the guidance range.
Why it matters: Higher cash from operations would show Lantheus is managing its capital well.
Supportive ifCash from operations increases by at least 10% quarter over quarter.
Worry ifCash from operations declines or stays flat.
Why it matters: Earnings per share is a key measure of profitability. A drop could signal deeper issues.
Worry ifAdjusted EPS for Q2 2026 is reported below $1.50.
Less concerning ifAdjusted EPS for Q2 2026 is reported above $1.50.
Why it matters: Sales growth of PYLARIFY is crucial for revenue growth. A rebound would show strong demand.
Supportive ifPYLARIFY sales increase year over year by more than 5% in Q2 2026.
Worry ifPYLARIFY sales decline year over year by more than 5% in Q2 2026.
Why it matters: Reaching these milestones may give extra cash to shareholders. This can increase value.
Supportive ifLantheus says it has reached the first goal for global prostate cancer tests by 2030.
Worry ifLantheus does not reach any milestones by the deadlines. This affects shareholder value.
Why it matters: More cash from operations helps Lantheus invest in growth and pay off debt.
Supportive ifCash from operations exceeds $130M in Q2.
Worry ifCash from operations drops below $120M in Q2.
Why it matters: DEFINITY sales are growing. This shows the market likes it and can increase revenue.
Supportive ifQ2 sales of DEFINITY increase year over year by more than 6.8%.
Worry ifQ2 sales of DEFINITY decline or grow less than 6.8% year over year.
Why it matters: Strong sales of PYLARIFY TruVu show that the market is accepting it and growing.
Supportive ifSales of PYLARIFY TruVu exceed $50 million in the first quarter after its launch.
Worry ifSales of PYLARIFY TruVu are below $20 million in the first quarter after its launch.
Why it matters: Higher operating income helps Lantheus make more money.
Supportive ifOperating income goes above 75% of the target.
Worry ifOperating income stays below 70% of the target.
Why it matters: Hitting these milestones could give more cash to shareholders. It shows the product's success.
Supportive ifLantheus reports achievement of at least one CVR milestone by the end of 2027.
Worry ifNo milestones are achieved by the end of 2027.
Why it matters: If PNT2003 is approved, Lantheus can offer more products. This will help it compete better.
Supportive ifFDA grants full approval for PNT2003, allowing for market launch.
Worry ifThe FDA may deny approval or delay the decision. This could happen beyond the expected timeline.
Why it matters: The merger will create a larger radiopharmaceutical company. This will help its market position.
Supportive ifThe merger will close in the first half of 2027. All regulatory approvals are in place.
Worry ifThe merger may be delayed or fail. This could happen due to regulatory or shareholder issues.